



Jubilant First Trust Healthcare sells its hospital business to Narayana Health

Kolkata (West Bengal), India, Monday, March 03, 2014

Jubilant First Trust Healthcare (JFTH), a wholly owned subsidiary of Jubilant Life Sciences sells its hospital business to Narayana Health. JFTH operates two hospitals in West Bengal, Kalpataru in Barasat and Rabindranath Thakur in Berhampore. The business has been transferred on a going concern basis as a slump sale which will enable Jubilant Life Sciences to focus on its core businesses in Pharmaceuticals and Life Sciences.

Commenting on the occasion, **Ms. Aashti Bhartia, Director Jubilant First Trust Healthcare** said, *"We entered the hospital business with the vision to build high quality and affordable healthcare. We are happy to hand over the hospitals to Narayana Health, whom we are confident of taking the vision forward."*

Speaking on the occasion, **Dr. A. Raghuvanshi, Vice Chairman, MD and Group CEO, Narayana Health** said, *"The acquisition of Jubilant First Trust Healthcare's hospital business in West Bengal is part of our strategic growth plan for East India. We have plans to upgrade the facilities at Jubilant Kalpataru Hospital in Kolkata to offer tertiary level super-speciality care in four to six months."* He further added, *"We are glad to include these hospitals into our network and reinforce our commitment to West Bengal in bringing high-class super-speciality healthcare services within the reach of the common man."*

Anand Rathi Advisors were the Investment Bankers for the deal.

About Jubilant First Trust Healthcare Limited

The Company is a wholly owned subsidiary of Jubilant Life Sciences.

For more information please contact:

For Investors

Ravi Agrawal
Jubilant Life Sciences Limited
Ph: +91-120 436 1002
E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar
Citigate Dewe Rogerson
Tel: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

For Media

Nidhi Malik
Jubilant Life Sciences Limited
Ph: +91-120 436 1062
E-mail: nidhi_malik@jubl.com

Sudipta Das
Perfect Relations
Ph: +91 9650602489
E-mail: sdas@perfectrelations.com



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.